Aliases & Classifications for Cerebral Palsy

MalaCards integrated aliases for Cerebral Palsy:

Name: Cerebral Palsy 38 12 76 53 54 29 55 6 43 3 15 73
Infantile Cerebral Palsy 12 73
Cerebral Palsy, Mixed 73
Mixed Cerebral Palsy 53
Palsy, Cerebral 40
Palsy Cerebral 76

Classifications:



External Ids:

Disease Ontology 12 DOID:1969
ICD10 33 G80 G80.9
ICD9CM 35 343.8
MeSH 44 D002547
NCIt 50 C34460

Summaries for Cerebral Palsy

NINDS : 54 The term cerebral palsy refers to a group of neurological disorders that appear in infancy or early childhood and permanently affect body movement, muscle coordination, and balance. CP affects the part of the brain that controls muscle movements.  The majority of children with cerebral palsy are born with it, although it may not be detected until months or years later. The early signs of cerebral palsy usually appear before a child reaches 3 years of age. The most common are a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a “scissored” gait; and muscle tone that is either too stiff or too floppy. Other neurological symptoms that commonly occur in individuals with CP include seizures, hearing loss and impaired vision, bladder and bowel control issues, and pain and abnormal sensations. A small number of children have CP as the result of brain damage in the first few months or years of life, brain infections such as bacterial meningitis or viral encephalitis, or head injury from a motor vehicle accident, a fall, or child abuse. The disorder isn't progressive, meaning that the brain damage typically doesn't get worse over time. Risk factors associated with CP do not cause the disorder but can increase a child's chance of being born with the disorder.CP is not hereditary.

MalaCards based summary : Cerebral Palsy, also known as infantile cerebral palsy, is related to inherited congenital spastic tetraplegia and spastic cerebral palsy, and has symptoms including athetosis, back pain and dystonia. An important gene associated with Cerebral Palsy is ADD3 (Adducin 3), and among its related pathways/superpathways are Vesicle-mediated transport and Clathrin derived vesicle budding. The drugs Dexmedetomidine and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include Blood and Umbilical Cord, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : 12 A brain disease that is caused by damage to the motor control centers of the developing brain during pregnancy, during childbirth or after birth, which affects muscle movement and balance.

NIH Rare Diseases : 53 Cerebral palsy refers to a group of neurological disorders that can affect the brain and/or spinal cord. Signs and symptoms generally appear during infancy or early childhood and vary based on the type of cerebral palsy (spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy), the severity of the condition and which area(s) of the brain are affected. Common features include a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a "scissored" gait; and muscle tone that is either too stiff or too floppy. Cerebral palsy is caused by abnormal brain development or damage to the developing brain. Most of these problems occur as the baby grows in the womb; however, they can happen at any time during the first 2 years of life. There is no cure for cerebral palsy, but treatment is available to alleviate some symptoms. This may include physical, occupational, and speech therapy; certain medications; surgery; and/or devices (i.e. braces, wheelchairs) to aid in mobility.

MedlinePlus : 43 Cerebral palsy is a group of disorders that affect a person's ability to move and to maintain balance and posture. The disorders appear in the first few years of life. Usually they do not get worse over time. People with cerebral palsy may have difficulty walking. They may also have trouble with tasks such as writing or using scissors. Some have other medical conditions, including seizure disorders or mental impairment. Cerebral palsy happens when the areas of the brain that control movement and posture do not develop correctly or get damaged. Early signs of cerebral palsy usually appear before 3 years of age. Babies with cerebral palsy are often slow to roll over, sit, crawl, smile, or walk. Some babies are born with cerebral palsy; others get it after they are born. There is no cure for cerebral palsy, but treatment can improve the lives of those who have it. Treatment includes medicines, braces, and physical, occupational and speech therapy. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 76 Cerebral palsy (CP) is a group of permanent movement disorders that appear in early childhood. Signs and... more...

Related Diseases for Cerebral Palsy

Diseases related to Cerebral Palsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 371)
# Related Disease Score Top Affiliating Genes
1 inherited congenital spastic tetraplegia 33.7 ADD3 GAD1 KANK1
2 spastic cerebral palsy 33.1 DMRT3 F5 GAD1 PLP1
3 hereditary spastic paraplegia 51 32.8 AP4B1 AP4S1
4 spastic paraplegia 50, autosomal recessive 32.7 AP4B1 AP4M1 AP4S1
5 hereditary spastic paraplegia 31.4 AP4B1 AP4M1 ATL1 PLP1
6 leukomalacia 31.3 IL6 TNF
7 chorioamnionitis 30.6 IL1B IL6 TNF
8 gingivitis 30.1 IL1B IL6 TNF
9 eclampsia 30.0 F2 F5 MTHFR TNF
10 thrombosis 29.9 F2 F5 MTHFR
11 pyelonephritis 29.9 IL1B IL6 TNF
12 schizencephaly 29.8 COL4A1 F5 MTHFR
13 stroke, ischemic 29.6 APOE F2 F5 MTHFR
14 pre-eclampsia 29.5 F2 F5 IL6 MTHFR TNF
15 porencephaly 29.5 COL4A1 F2 F5 MTHFR
16 juvenile rheumatoid arthritis 29.4 IL1B IL6 LTA TNF
17 arthritis 29.1 IL1B IL6 LTA TNF
18 multiple sclerosis 28.4 APOE IL1B IL6 LTA PLP1 TNF
19 cerebral palsy, ataxic, autosomal recessive 12.7
20 spastic diplegia cerebral palsy 12.5
21 dyskinetic cerebral palsy 12.5
22 cerebral palsy athetoid 12.4
23 cerebral palsy, spastic quadriplegic, 1 12.4
24 mixed cerebral palsy 12.3
25 cerebral palsy, spastic quadriplegic, 2 12.3
26 cerebral palsy, spastic quadriplegic, 3 12.3
27 spastic quadriplegia 12.2
28 spastic hemiplegia 12.2
29 spastic diplegia 12.2
30 spastic monoplegia 12.0
31 spasticity 11.5
32 periventricular leukomalacia 11.5
33 intellectual disability - athetosis - microphthalmia 11.4
34 suprabulbar paresis, congenital 11.3
35 swallowing disorders 11.3
36 spastic paraplegia 47, autosomal recessive 11.3
37 spastic paraplegia 52, autosomal recessive 11.3
38 athetosis 11.2
39 hypertonia 11.2
40 dysphagia 11.2
41 neonatal stroke 11.2
42 developmental coordination disorder 11.2
43 foot drop 11.2
44 hypotonia 11.2
45 cerebellar ataxia, mental retardation, and dysequilibrium syndrome 1 11.2
46 infantile hypotonia 11.2
47 spastic paraplegia 51, autosomal recessive 11.2
48 cerebritis 11.1
49 spastic paraplegia 20, autosomal recessive 11.1
50 spastic paraplegia 2, x-linked 11.1

Comorbidity relations with Cerebral Palsy via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Cerebral Palsy:



Diseases related to Cerebral Palsy

Symptoms & Phenotypes for Cerebral Palsy

UMLS symptoms related to Cerebral Palsy:


athetosis, back pain, dystonia, headache, muscle rigidity, pain, sciatica, seizures, syncope, torticollis, tremor, chronic pain, muscle fibrillation, asterixis, abnormality of extrapyramidal motor function, involuntary movements, vertigo/dizziness, myokymia, sleeplessness

MGI Mouse Phenotypes related to Cerebral Palsy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.27 AP4B1 AP4E1 APOE ATL1 COL4A1 DMRT3
2 growth/size/body region MP:0005378 10.18 AP4E1 APOE COL4A1 F2 F5 GAD1
3 homeostasis/metabolism MP:0005376 10.18 AP4E1 AP4M1 APOE COL4A1 F2 F5
4 cardiovascular system MP:0005385 10.13 COL4A1 F2 F5 IL1B IL6 LTA
5 nervous system MP:0003631 10.1 F2 F5 GAD1 IL1B IL6 LTA
6 limbs/digits/tail MP:0005371 9.87 AP4E1 APOE ATL1 GAD1 LTA MTHFR
7 respiratory system MP:0005388 9.7 F2 GAD1 IL6 LTA TNF APOE
8 skeleton MP:0005390 9.7 IL6 LTA MTHFR PLP1 TNF AP4E1
9 vision/eye MP:0005391 9.23 AP4E1 APOE COL4A1 IL6 LTA MTHFR

Drugs & Therapeutics for Cerebral Palsy

Drugs for Cerebral Palsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
2
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Levodopa Approved Phase 4 59-92-7 6047
5
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-84-3 187
6
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1 1134-47-0 2284
7
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 7487-88-9 24083
8
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
9
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
10
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
11
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
12 Adrenergic Agents Phase 4,Phase 2,Phase 1
13 Adrenergic Agonists Phase 4,Phase 2,Phase 1
14 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 1
15 Adrenergic alpha-Agonists Phase 4,Phase 1
16 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Analgesics, Non-Narcotic Phase 4,Phase 3,Not Applicable
18 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable
19 Anesthetics, General Phase 4,Not Applicable
20 Anesthetics, Inhalation Phase 4,Not Applicable
21 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
22 Hypnotics and Sedatives Phase 4,Not Applicable
23 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Platelet Aggregation Inhibitors Phase 4,Not Applicable
26 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Carbidopa, levodopa drug combination Phase 4
28 Dihydroxyphenylalanine Phase 4
29 Dopamine Agents Phase 4
30 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 abobotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Botulinum Toxins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Botulinum Toxins, Type A Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Neuromuscular Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 onabotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2,Not Applicable
38 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 calcium channel blockers Phase 4,Phase 3,Phase 2,Not Applicable
40 Calcium, Dietary Phase 4,Phase 3,Phase 2,Not Applicable
41 Tocolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
42 Epoetin alfa Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113427-24-0
43 Hematinics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 incobotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable
45 Anesthetics, Local Phase 4,Not Applicable
46 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Anesthetics, Intravenous Phase 4,Not Applicable
48 calcium heparin Phase 4
49 Acidophilus Nutraceutical Phase 4
50 Sunflower Nutraceutical Phase 4

Interventional clinical trials:

(show top 50) (show all 690)
# Name Status NCT ID Phase Drugs
1 Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy Unknown status NCT02244515 Phase 4 dexmedetomidine
2 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
3 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
4 The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy Unknown status NCT01256021 Phase 4 Botulinum Toxin Type A
5 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Unknown status NCT00752934 Phase 4 oral baclofen + placebo;placebo + oral baclofen
6 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
7 Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases Unknown status NCT00796380 Phase 4 Xingnaojing
8 Alterations of Functional Activities and Leg Stiffness After Hamstring Lengthening in Cerebral Palsy Children Completed NCT00154830 Phase 4
9 Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral Palsy Completed NCT01276015 Phase 4 Botulinum Toxin Type A
10 Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy Completed NCT01860196 Phase 4 Meditoxin;Normal saline
11 Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies Completed NCT00964639 Phase 4 Ropivacaine;Saline
12 Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy Completed NCT00432055 Phase 4 Botulinum toxin type A (Botox);placebo (saline)
13 Recurrent Crying Spells in Cerebral Palsy Completed NCT01955655 Phase 4 Baclofen
14 Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth Completed NCT00120588 Phase 4 magnesium
15 Effect of Erythropoietin on Preterm Brain Injury Completed NCT02036073 Phase 4 recombinant human erythropoietin
16 Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Recruiting NCT02546999 Phase 4 botox;placebo
17 Synbiotic, Prebiotics and Probiotics in Children With Cerebral Palsy and Constipation Recruiting NCT03117322 Phase 4
18 Intrathecal (IT) Baclofen Drug Distribution Recruiting NCT02903823 Phase 4 Baclofen bolus injection
19 A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging Active, not recruiting NCT02633241 Phase 4 Dexmedetomidine-Propofol
20 Effects of Transfusion Thresholds on Neurocognitive Outcome of Extremely Low Birth Weight Infants Active, not recruiting NCT01393496 Phase 4
21 Changes of Gas Values in Cord Blood Versus Time and Temperature Not yet recruiting NCT02785367 Phase 4
22 Improvement After Botulinum Toxin Injections to the Arms in Children With Cerebral Palsy Terminated NCT00549471 Phase 4
23 Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy Withdrawn NCT01386255 Phase 4 Baclofen;placebo
24 Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below 15 Years Unknown status NCT01832454 Phase 2, Phase 3
25 Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy Unknown status NCT01489904 Phase 2, Phase 3
26 Targeted Hip Strength Training in Children With Cerebral Palsy (CP) Unknown status NCT01633736 Phase 3
27 Modulation of Brain Plasticity After Perinatal Stroke Unknown status NCT01189058 Phase 2, Phase 3
28 Magnesium Sulfate to Prevent Brain Injury in Premature Infants Unknown status NCT00065949 Phase 3 magnesium sulfate
29 Efficacy Study of Hypothermia Plus Magnesium Sulphate(MgSO4) in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy Unknown status NCT01646619 Phase 3 Magnesium Sulphate;Placebo
30 Phase III Clinical Trial of "Botulax®" to Treat Children With Cerebral Palsy Completed NCT01787344 Phase 3 Botulinum Toxin Type A(Botox®);Botulinum toxin type A(Botulax®)
31 Orthotics in Ambulatory Cerebral Palsy Completed NCT01527162 Phase 3
32 The Post-Operative Pain in Cerebral Palsy (POPPIES) Trial Completed NCT01437644 Phase 3 botulinum toxin intramuscular injection
33 Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy Completed NCT00261131 Phase 3 Botulinum Toxin A
34 Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Patients With Cerebral Paralysis Completed NCT01929434 Phase 3
35 Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy Completed NCT01893411 Phase 3 IncobotulinumtoxinA (16 Units per kg body weight);IncobotulinumtoxinA (12 Units per kg body weight);IncobotulinumtoxinA (4 Units per kg body weight)
36 Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy Completed NCT01905683 Phase 3 IncobotulinumtoxinA (16-20 Units per kg body weight)
37 Dutch National ITB Study in Children With Cerebral Palsy Completed NCT00367068 Phase 3 baclofen, intrathecal
38 Static and Dynamic Postural Stability in Cerebral Palsy Children Completed NCT01799304 Phase 3
39 A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years Completed NCT01898520 Phase 3 Sativex;Placebo
40 Efficacy of Intermittent Serial Casting on Spastic Wrist Flexion Deformity Completed NCT03306212 Phase 3 Botulinum toxin A
41 Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions Completed NCT00491894 Phase 3 Oral Glycopyrrolate Liquid
42 Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles Completed NCT00133861 Phase 2, Phase 3 Botulinum toxin
43 Dysport® Pediatric Lower Limb Spasticity Follow-on Study Completed NCT01251380 Phase 3 Botulinum type A toxin (Dysport®)
44 Dysport® Pediatric Lower Limb Spasticity Study Completed NCT01249417 Phase 3 Botulinum type A toxin (Dysport®);Placebo
45 Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) Completed NCT00014989 Phase 3 magnesium sulfate
46 Individualized Neurodevelopmental Treatment Completed NCT00922077 Phase 3
47 MEOPA to Improve Physical Therapy Results After Multilevel Surgery Completed NCT00632528 Phase 3 MEOPA;Medicinal air
48 Calcium Channel Blockers Compared to Magnesium Sulfate in Fetal Cerebral Blood Flow Completed NCT02591004 Phase 2, Phase 3 Magesium sulphate;Nifedipine
49 BOTOX® Treatment in Pediatric Lower Limb Spasticity Completed NCT01603628 Phase 3 Normal Saline (Placebo)
50 BOTOX® Treatment in Pediatric Upper Limb Spasticity Completed NCT01603602 Phase 3 Normal Saline (Placebo)

Search NIH Clinical Center for Cerebral Palsy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cerebral Palsy cell therapies at LifeMap Discovery.

Genetic Tests for Cerebral Palsy

Genetic tests related to Cerebral Palsy:

# Genetic test Affiliating Genes
1 Cerebral Palsy 29

Anatomical Context for Cerebral Palsy

MalaCards organs/tissues related to Cerebral Palsy:

41
Brain, Bone, Testes, Spinal Cord, Heart, Tongue, Lung
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cerebral Palsy:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Cerebral Palsy

Articles related to Cerebral Palsy:

(show top 50) (show all 1634)
# Title Authors Year
1
The continually changing epidemiology of cerebral palsy. ( 29430775 )
2018
2
O 026 - Negative impact of muscle weakness and spasticity on gait in children with unilateral cerebral palsy. ( 29954655 )
2018
3
Management of hypertonia in cerebral palsy. ( 29135566 )
2018
4
Comparative study of home and community participation among children with and without cerebral palsy. ( 29957491 )
2018
5
Prevalence of sleep problems and sleep-related characteristics in preschool- and school-aged children with cerebral palsy. ( 29966807 )
2018
6
Medial gastrocnemius structure and gait kinetics in spastic cerebral palsy and typically developing children: A cross-sectional study. ( 29794756 )
2018
7
Dynamic spasticity determines hamstring length and knee flexion angle during gait in children with spastic cerebral palsy. ( 29960141 )
2018
8
Manual dexterity, but not cerebral palsy, predicts cognitive functioning after neonatal stroke. ( 29624666 )
2018
9
Learning to cope with mirror movements in unilateral spastic cerebral palsy: a brief report. ( 29787338 )
2018
10
The natural history of crouch gait in bilateral cerebral palsy: A systematic review. ( 29960128 )
2018
11
Clinical characteristics and functional status of children with different subtypes of dyskinetic cerebral palsy. ( 29794768 )
2018
12
Bike skills training for children with cerebral palsy: protocol for a randomised controlled trial. ( 29431140 )
2018
13
Dorsal rhizotomy for children with spastic diplegia of cerebral palsy origin: usefulness of intraoperative monitoring. ( 29652243 )
2018
14
Validation of reaching in a virtual environment in typically developing children and children with mild unilateral cerebral palsy. ( 29427357 )
2018
15
Trunk control and functionality in children with spastic cerebral palsy. ( 29652201 )
2018
16
Effects of ultrasound-guided botulinum toxin type-A injections with a specific approach in spastic cerebral palsy. ( 29694645 )
2018
17
Contribution of perinatal conditions to cerebral palsy in Uganda. ( 29433660 )
2018
18
Muscle morphology of the lower leg in ambulant children with spastic cerebral palsy. ( 29981242 )
2018
19
Surgical reconstruction of hip subluxation and dislocation in children with cerebral palsy. ( 29526153 )
2018
20
Age trajectories of musculoskeletal morbidities in adults with cerebral palsy. ( 29981509 )
2018
21
Slip avoidance strategies in children with bilateral spastic cerebral palsy and crouch gait. ( 29679933 )
2018
22
<i>TSEN54</i> Gene-Related Pontocerebellar Hypoplasia Type 2 Could Mimic Dyskinetic Cerebral Palsy with Severe Psychomotor Retardation. ( 29410950 )
2018
23
Identification of a candidate enhancer for DMRT3 involved in spastic cerebral palsy pathogenesis. ( 29305858 )
2018
24
Functional capacity in adults with cerebral palsy: Lower limb muscle strength matters. ( 29438658 )
2018
25
Development of postural control in infancy in cerebral palsy and cystic periventricular leukomalacia. ( 29787891 )
2018
26
Virtual reality training for children with unilateral cerebral palsy. ( 29442357 )
2018
27
The Relationship Between Hand Function and Overlapping Motor Representations of the Hands in the Contralesional Hemisphere in Unilateral Spastic Cerebral Palsy. ( 29303031 )
2018
28
Re-engineering the interpretation of electronic fetal monitoring to identify reversible risk for cerebral palsy: a case control series. ( 29447043 )
2018
29
Relationship between radiographic patella-alta pathology and walking dysfunction in children with bilateral spastic Cerebral Palsy. ( 29149666 )
2018
30
An Unreported Cause of Intrathecal Baclofen Withdrawal Symptoms in a Woman With Spastic Cerebral Palsy Who Received Intrathecal Gablofen. ( 29521737 )
2018
31
O 023 - Crouch gait in children with Cerebral Palsy and the impact on trunk kinematics and lower lumbar spinal loading. ( 29980441 )
2018
32
Path analysis of strength, spasticity, gross motor function, and health-related quality of life in children with spastic cerebral palsy. ( 29673348 )
2018
33
Estimating medial gastrocnemius muscle volume in children with spastic cerebral palsy: a cross-sectional investigation. ( 29067675 )
2018
34
Determine the Relationship Between Abdominal Muscle Strength, Trunk Control and Urinary Incontinence in Children with Diplegic Cerebral Palsy. ( 29427287 )
2018
35
Needs for Medical and Rehabilitation Services in Adults With Cerebral Palsy in Korea. ( 29961745 )
2018
36
Pharmacological and neurosurgical interventions for managing dystonia in cerebral palsy: a systematic review. ( 29405267 )
2018
37
Casting Protocols Following BoNT-A Injections to Treat Spastic Hypertonia of the Triceps Surae in Children with Cerebral Palsy and Equinus Gait: A Randomized Controlled Trial. ( 29771161 )
2018
38
Incidence of Cerebral Palsy in Korea and the Effect of Socioeconomic Status: A Population-Based Nationwide Study. ( 29978615 )
2018
39
Prophylactic antibiotics in soft-tissue procedures in children with cerebral palsy. ( 29951128 )
2018
40
Fifteen-minute consultation: Management of the upper limb in unilateral cerebral palsy. ( 29970591 )
2018
41
Deep brain stimulation for dystonia due to cerebral palsy: A review. ( 29396170 )
2018
42
O 037 - Estimating musculotendon forces in children with cerebral palsy: The importance of the use of electromyography in neuromusculoskeletal modelling. ( 29954656 )
2018
43
Severity of cerebral palsy and likelihood of adverse events after botulinum toxin A injections. ( 29451702 )
2018
44
Knee contracture in children with cerebral palsy: association with muscle lengths. ( 29451692 )
2018
45
Comparison of calf muscle architecture between Asian children with spastic cerebral palsy and typically developing peers. ( 29304114 )
2018
46
Changes in Tactile Function During Intensive Bimanual Training in Children With Unilateral Spastic Cerebral Palsy. ( 29433419 )
2018
47
Co-occurrence and Severity of Neurodevelopmental Burden (Cognitive Impairment, Cerebral Palsy, Autism Spectrum Disorder, and Epilepsy) at Age Ten Years in Children Born Extremely Preterm. ( 29310907 )
2018
48
O 025-Kinematic and strength determinants of step length and step frequency in children and adolescents with cerebral palsy. ( 29970279 )
2018
49
Child's quality of life and mother's burden in spastic cerebral palsy: a topographical classification perspective. ( 29690795 )
2018
50
Health professionals' experiences and barriers encountered when implementing hip surveillance for children with cerebral palsy. ( 29975007 )
2018

Variations for Cerebral Palsy

ClinVar genetic disease variations for Cerebral Palsy:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 ADD3 NM_016824.4(ADD3): c.1100G> A (p.Gly367Asp) single nucleotide variant Pathogenic rs564185858 GRCh37 Chromosome 10, 111882007: 111882007
2 ADD3 NM_016824.4(ADD3): c.1100G> A (p.Gly367Asp) single nucleotide variant Pathogenic rs564185858 GRCh38 Chromosome 10, 110122249: 110122249
3 46;XX;t(1;5)(p31;q33)dn Translocation Likely pathogenic
4 46;XY;t(6;16)(p21.1;q21)dn Translocation Uncertain significance

Expression for Cerebral Palsy

Search GEO for disease gene expression data for Cerebral Palsy.

Pathways for Cerebral Palsy

Pathways related to Cerebral Palsy according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.27 AP4B1 AP4E1 AP4M1 AP4S1 APOE COL4A1
2
Show member pathways
12.29 AP4B1 AP4E1 AP4M1 AP4S1
3
Show member pathways
12.15 IL1B IL6 LTA TNF
4 12.05 IL1B IL6 PLP1 TNF
5 11.89 AP4B1 AP4E1 AP4M1 AP4S1
6 11.86 COL4A1 IL1B IL6 TNF
7 11.8 IL1B IL6 TNF
8 11.79 IL1B LTA TNF
9
Show member pathways
11.77 APOE F2 IL1B IL6 MTHFR TNF
10 11.76 IL1B IL6 TNF
11 11.74 IL1B IL6 LTA TNF
12 11.7 IL1B LTA TNF
13 11.66 IL1B IL6 TNF
14 11.66 COL4A1 IL1B IL6 TNF
15 11.64 IL1B IL6 TNF
16 11.6 COL4A1 IL1B IL6 TNF
17 11.57 IL1B IL6 TNF
18
Show member pathways
11.56 IL1B IL6 TNF
19 11.48 IL1B IL6 TNF
20 11.42 IL1B IL6 TNF
21 11.41 IL1B IL6 TNF
22 11.24 IL1B IL6 TNF
23 11.23 IL1B IL6 TNF
24 11.14 IL1B IL6 TNF
25 11.11 APOE IL1B IL6 TNF
26 11.09 IL1B IL6 TNF
27 10.71 COL4A1 IL6 TNF
28 10.42 IL1B IL6 MTHFR TNF

GO Terms for Cerebral Palsy

Cellular components related to Cerebral Palsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.92 APOE COL4A1 F2 F5 IL1B IL6
2 endoplasmic reticulum lumen GO:0005788 9.65 APOE COL4A1 F2 F5 IL6
3 trans-Golgi network membrane GO:0032588 9.46 AP4B1 AP4E1 AP4M1 AP4S1
4 endosome lumen GO:0031904 9.26 AP4B1 AP4E1 AP4M1 AP4S1
5 AP-4 adaptor complex GO:0030124 8.92 AP4B1 AP4E1 AP4M1 AP4S1

Biological processes related to Cerebral Palsy according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.93 F2 IL1B IL6 LTA TNF
2 cellular protein metabolic process GO:0044267 9.87 APOE F2 F5 IL6
3 humoral immune response GO:0006959 9.67 IL6 LTA TNF
4 positive regulation of interleukin-6 production GO:0032755 9.65 IL1B IL6 TNF
5 positive regulation of interferon-gamma production GO:0032729 9.61 IL1B LTA TNF
6 negative regulation of growth of symbiont in host GO:0044130 9.59 LTA TNF
7 locomotory exploration behavior GO:0035641 9.58 APOE GAD1
8 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.58 IL1B TNF
9 negative regulation of lipid storage GO:0010888 9.56 IL6 TNF
10 negative regulation of platelet activation GO:0010544 9.55 APOE F2
11 positive regulation of chemokine biosynthetic process GO:0045080 9.52 IL1B TNF
12 regulation of establishment of endothelial barrier GO:1903140 9.51 IL1B TNF
13 positive regulation of fever generation GO:0031622 9.46 IL1B TNF
14 protein localization GO:0008104 9.46 AP4B1 AP4E1 AP4M1 AP4S1
15 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.4 LTA TNF
16 sequestering of triglyceride GO:0030730 9.37 IL1B TNF
17 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.32 IL1B TNF
18 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.26 LTA TNF
19 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.13 APOE IL1B TNF
20 protein targeting GO:0006605 8.92 AP4B1 AP4E1 AP4M1 AP4S1

Molecular functions related to Cerebral Palsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IL1B IL6 LTA TNF

Sources for Cerebral Palsy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....